|Bid||0.00 x 800|
|Ask||399.14 x 1000|
|Day's range||378.03 - 383.70|
|52-week range||219.23 - 401.78|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||27.03|
|Earnings date||31 Jan 2023 - 06 Feb 2023|
|Forward dividend & yield||2.16 (0.56%)|
|Ex-dividend date||30 Nov 2022|
|1y target est||414.79|
Masimo's (MASI) SpHb is likely to enhance transfusion management and post-operative patient outcomes on patients.
Investors are optimistic about Merit Medical's (MMSI) slew of product launches.
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.